Friday, 16 October 2026European Markets

IMERYS And AIR LIQUIDE Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - imerys (nk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
imerys (nk.pa) €30.82 6.12% 3.79%
air liquide (ai.pa) €167.36 1.67% 13.73%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. imerys (nk.pa)

6.12% forward dividend yield and 3.79% return on equity

imerys s.a. provides mineral-based specialty solutions for various industries worldwide. the company operates through performance minerals and high temperature materials and solutions segments. it provides additives for interior decorative paints, as well as marine protection, facade coating, can coating; and adhesives and sealants. in addition, the company offers minerals for technical ceramics and traditional ceramics comprising floor and wall tiles, large slabs, sanitaryware, and tableware; and components for the production of high purity silicon metal for used to manufacture aluminum alloys, electronics, and solar panels, as well as for construction industry, such as insulation ceiling tiles. further, it provides functional additives for plastics and thermoset for use in construction and infrastructure industries; fillers and coatings for board and packaging applications; filtration agents for liquids and blood plasma; and graphite and carbon-based solutions for lithium-ion and alkaline batteries, polymers, fuel cells, carbon brushes, and others. additionally, the company offers refractory minerals and solutions for high-temperature processes; alumina and zirconia for abrasives; and high-performance binders for dry mix mortars and floor screeds in the construction industry. it serves automotive and transportation, consumer and health care, energy and electronics, industry and equipment, iron, and steel industries. the company was incorporated in 1880 and is headquartered in paris, france. imerys s.a. is a subsidiary of belgian securities bv.

earnings per share

as for profitability, imerys has a trailing twelve months eps of €1.67.

pe ratio

imerys has a trailing twelve months price to earnings ratio of 18.46. meaning, the purchaser of the share is investing €18.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.79%.

volume

today's last reported volume for imerys is 38371 which is 54.03% below its average volume of 83478.

more news about imerys.

2. air liquide (ai.pa)

1.67% forward dividend yield and 13.73% return on equity

l'air liquide s.a. provides gases, technologies, and services for the industrial and health sectors in europe, the americas, the asia pacific, the middle east, and africa. the gas & services segment comprises large industries business, which offers gas and energy solutions including oxygen, nitrogen, argon, hydrogen, and carbon monoxide, as well as operates cogeneration plants to supply steam and electricity to metals, chemicals, refining, and energy industries; and industrial merchant business line provides industrial gases, equipment, hardgoods, and associated services to material and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sector. this segment also includes healthcare business, which provides medical gases, home healthcare services, medical equipment, and specialty ingredient to patients, healthcare professionals, and hospitals; and electronic business supply carrier gases, electronic specialty and advanced materials, equipment and installation, and service to semiconductor, flat panel, and photovoltaic markets. its engineering & construction segment designs, develops, and builds industrial gas production plants to third parties; and design and manufacture plants in traditional, renewable and alternative energy sectors. the global markets & technologies segment delivers technological solutions, such as molecules, equipment, and services to energy transition, primarily in transport, energy, and waste valorization, as well as space exploration, aerospace, fundamental sciences, and quantum computing. this segment also invests in biomethane production units; develops stations for distributing natural biogas for vehicles and hydrogen; operates biomethane production units for maritime industry; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. l'air liquide s.a. was incorporated in 1902 and is headquartered in paris, france.

earnings per share

as for profitability, air liquide has a trailing twelve months eps of €6.07.

pe ratio

air liquide has a trailing twelve months price to earnings ratio of 27.57. meaning, the purchaser of the share is investing €27.57 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.73%.

more news about air liquide.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com